Panitumumab Treatment: Dosage, Side Effects, and Uses Explained

Summary or Key Points

Panitumumab is a targeted therapy used to treat certain cancers, including colorectal and head and neck cancers. It works by blocking the growth of cancer cells. Panitumumab is administered through intravenous (IV) infusion, typically in a hospital or clinic setting. Common side effects include skin reactions and fatigue. Always consult your healthcare provider before starting or adjusting your Panitumumab treatment plan.

Names of Medication

US Brand Name: Vectibix

Generic Name: Panitumumab

The generic name refers to the active ingredient, while the brand name is assigned by the manufacturer. In this article, the generic name will be used in parentheses.

Pharmacologic Category

Monoclonal Antibody

EGFR Inhibitor (Epidermal Growth Factor Receptor Inhibitor)

Panitumumab Dosage

Panitumumab is prescribed to treat various cancers. The dosage schedule depends on the specific type of cancer being treated. Always follow your doctor’s instructions and consult them before making any changes to your dose. You can also schedule a telemedicine appointment with one of our providers for personalized care.

Panitumumab for Colorectal Cancer

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Head and Neck Cancer

Dosage: 9 mg/kg administered as an IV infusion every 21 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Non-Small Cell Lung Cancer

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Esophageal Cancer

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Gastric Cancer

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Pancreatic Cancer

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Biliary Tract Cancer

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Squamous Cell Carcinoma

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Metastatic Cancer

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Panitumumab for Cancer of Unknown Primary Origin

Dosage: 6 mg/kg administered as an IV infusion every 14 days.

Length of Treatment: Treatment continues until disease progression or unacceptable toxicity occurs.

Dosage Forms and Strengths

Panitumumab is available in the following dosage forms:

1. Injection, solution: 100 mg/5 mL (20 mg/mL)
2. Injection, solution: 400 mg/20 mL (20 mg/mL)

Administration Instructions for Panitumumab

Panitumumab is administered as an intravenous (IV) infusion, meaning it is delivered directly into a vein. The infusion is typically performed in a hospital or clinic under the supervision of a healthcare professional. Depending on the dose, the infusion may take between 60 and 90 minutes. Follow your doctor’s instructions carefully and report any side effects during or after the infusion. If you have concerns about your treatment, you can also consult one of our telemedicine providers.

Contraindications

A contraindication is a specific condition where a treatment or medication should not be used because it may be harmful. If you have any of the following conditions, Panitumumab may not be safe for you:

1. Allergic reactions to Panitumumab: If you have had a severe allergic reaction to Panitumumab or its ingredients, you should not take this medication. Symptoms of an allergic reaction may include rash, itching, swelling, dizziness, or difficulty breathing.
2. Severe electrolyte imbalances: Panitumumab can cause or worsen low levels of electrolytes such as magnesium, potassium, and calcium. If you already have an imbalance, Panitumumab could make it worse, potentially leading to serious complications like heart problems or muscle weakness.
3. Interstitial lung disease: This group of lung conditions causes scarring of lung tissue. Panitumumab has been associated with lung toxicity, and if you have a history of lung disease, it may increase your risk of serious lung complications.
4. Severe skin reactions: Panitumumab can cause severe skin reactions, including infections. If you have a history of skin conditions or are prone to infections, this medication may not be suitable for you.

Drug to Drug Interactions

Panitumumab can interact with other medications, potentially affecting its effectiveness or increasing the risk of side effects. Be sure to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medications, and herbal supplements. Known interactions include:

1. Bevacizumab (Avastin): Combining Panitumumab with Bevacizumab can increase the risk of serious side effects, including gastrointestinal perforation (a hole in the stomach or intestines).
2. Oxaliplatin (Eloxatin): Panitumumab may reduce the effectiveness of Oxaliplatin, a chemotherapy drug used to treat colorectal cancer.
3. Fluorouracil (Adrucil): This chemotherapy drug may interact with Panitumumab, increasing the risk of severe side effects, including gastrointestinal and skin toxicities.
4. Live vaccines: Panitumumab can weaken your immune system, making live vaccines (such as MMR or chickenpox) less effective or increasing the risk of infection from the vaccine itself.

Panitumumab in Pregnancy

Is it safe to take Panitumumab when pregnant?

Panitumumab is generally not recommended during pregnancy, as it may interfere with fetal development and potentially harm the unborn baby. If you are pregnant or planning to become pregnant, it’s important to discuss alternative treatment options with your healthcare provider. Women of childbearing age should use effective contraception during Panitumumab treatment and for at least six months after the final dose. If you become pregnant while receiving Panitumumab, contact your healthcare provider immediately for guidance.

Panitumumab while Breastfeeding

Is it safe to take Panitumumab while breastfeeding?

Breastfeeding is not advised during Panitumumab treatment. Although it is unclear whether Panitumumab passes into breast milk, there is a potential risk of serious side effects for a nursing infant. To minimize this risk, avoid breastfeeding during treatment and for at least two months after your last dose. If you are currently breastfeeding or planning to breastfeed, consult your healthcare provider to discuss the safest course of action for both you and your baby.

Estimated Cost of Panitumumab

The cost of Panitumumab can vary depending on your location and the pharmacy you use. Without insurance, a 30-day supply may range from $10,000 to $15,000 when using a GoodRX coupon. Given the high cost, it’s important to explore insurance coverage, patient assistance programs, or other financial support options with your healthcare provider or pharmacist to help manage expenses.

Possible Alternatives to Panitumumab

If Panitumumab is not suitable for your treatment, there are alternative therapies available depending on the type of cancer you have. Always consult your healthcare provider before making any changes to your treatment plan. You can also schedule a telemedicine appointment with one of our providers to discuss your options in more detail.

Colorectal Cancer Alternatives

For colorectal cancer, alternatives to Panitumumab include chemotherapy regimens such as FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or targeted therapies like Bevacizumab (Avastin). In addition to medical treatments, lifestyle changes—such as maintaining a healthy diet, engaging in regular physical activity, and avoiding smoking—may also contribute to better outcomes.

Head and Neck Cancer Alternatives

Treatment options for head and neck cancer may include radiation therapy, surgery, or chemotherapy with drugs like Cisplatin. Quitting smoking and reducing alcohol consumption can significantly enhance the effectiveness of these treatments.

Non-Small Cell Lung Cancer Alternatives

For non-small cell lung cancer, alternatives to Panitumumab include immunotherapy drugs like Pembrolizumab (Keytruda) or chemotherapy with Carboplatin. Smoking cessation is critical for improving treatment outcomes and overall health.

Esophageal Cancer Alternatives

Treatment options for esophageal cancer may involve surgery, radiation therapy, or chemotherapy with drugs such as Paclitaxel (Taxol). Dietary adjustments, like eating smaller, more frequent meals, can also help manage symptoms and improve quality of life.

Gastric Cancer Alternatives

For gastric cancer, alternatives to Panitumumab include chemotherapy with drugs like Capecitabine (Xeloda) or radiation therapy. A diet rich in fruits and vegetables and low in processed foods may support overall health and complement medical treatments.

Pancreatic Cancer Alternatives

Treatment options for pancreatic cancer may include chemotherapy with drugs like Gemcitabine (Gemzar) or surgery. Maintaining a healthy weight and avoiding tobacco products are important lifestyle changes that can positively impact treatment outcomes.

Biliary Tract Cancer Alternatives

For biliary tract cancer, alternatives to Panitumumab include surgery, radiation therapy, or chemotherapy with drugs like Cisplatin. Supporting liver health through a balanced diet and avoiding alcohol can also play a role in overall treatment success.

Squamous Cell Carcinoma Alternatives

Treatment options for squamous cell carcinoma may include surgery, radiation therapy, or topical treatments like 5-fluorouracil (Efudex). Protecting your skin from excessive UV exposure is a key preventive measure to reduce the risk of recurrence.

Metastatic Cancer Alternatives

Treatment for metastatic cancer depends on the primary cancer type but may involve systemic therapies such as chemotherapy, immunotherapy, or targeted therapies. Palliative care and symptom management are also important aspects of treatment for advanced cancer.

Cancer of Unknown Primary Origin Alternatives

Treatment options for cancer of unknown primary origin may include chemotherapy, radiation therapy, or immunotherapy, depending on the suspected origin of the cancer. Genetic testing may provide valuable insights to guide treatment decisions and improve outcomes.

Recent Updates on Panitumumab Research

Recent research on Panitumumab has focused on its use in combination with other therapies to improve outcomes for patients with metastatic colorectal cancer. A 2022 study found that combining Panitumumab with chemotherapy regimens like FOLFIRI (fluorouracil, leucovorin, and irinotecan) can improve survival rates in patients with RAS wild-type colorectal cancer. Additionally, ongoing clinical trials are investigating Panitumumab’s potential in other cancers, including head and neck cancer and non-small cell lung cancer, particularly when combined with immunotherapy agents.

As research continues to evolve, new findings may offer more personalized treatment options. It’s important to discuss the latest research with your healthcare provider to determine whether Panitumumab is the right choice for your condition. You can also schedule a telemedicine appointment with one of our providers to explore the most current treatment options available to you.

James Kingsley

Learn More